In conclusion, our results provide, for the first time, clinical and experimental evidence that ClC-3 expression is closely associated with cervical carcinoma development and poor survival, indicating ClC-3 may be a patent tumour marker, an expected prognostic indicator and a latent therapeutic target for cervical carcinoma. Here, CLCN3 is linked to neoplasm.